Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand
Executive Summary
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
You may also be interested in...
FDA Idea To ‘Encourage Competition For New Drugs’ Spares Cutting OTC Switch Market Exclusivity
“FDA is seeking to encourage competition for new drugs by proposing to amend the Hatch-Waxman 3-year exclusivity provisions to ensure that this exclusivity is limited to situations where the new drug applicant is actually seeking such exclusivity,” according to legislative proposals document.
Haleon’s ‘#1 Doctor Recommended’ Voltaren Claim Challenged By RB Clears NAD Review With Caveat
NAD says in advertising without references to arthritis, Haleon should ensure claim Reckitt challenged “clearly and conspicuously discloses that Voltaren is approved for the treatment of arthritis pain.” Haleon supports “#1 Doctor Recommended” and “#1 Topical Pain Reliever Globally” claims.
Bayer Spreads Aleve Brand Into Topical Pain Relief
Three-product AleveX line contains menthol and camphor for minor muscle and joints aches and pains with a cooling sensation. Bayer Healthcare promotes launch with an ad campaign featuring basketball legend and TV personality Charles Barkley.